ImmTAC Expansion

Immunocore is broadening its ImmTAC platform beyond Kimmtrak. The ImmTAX technology is in clinical testing for solid tumors, infectious diseases, and autoimmune conditions. Brenetafusp, a lead candidate, is in phase III for first‑line advanced cutaneous melanoma, while other programs target colorectal and gastrointestinal cancers. Expansion into non‑oncology indications offers higher rewards but faces intensified competition from established players with deeper resources.